Experience with sonidegib in patients with advanced basal cell carcinoma: case reports
Drugs in Context · 19.05.2022 · 11 · 1-8
DOI: 10.7573/dic.2022-3-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 19.05.2022. Verfasst von Susana Puig und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain.
- CIBERER, Instituto de salud Carlos III, Barcelona, Spain.
- Department of Dermatology, Instituto Valenciano de Oncología (IVO), Valencia, Spain.
- Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain.
- Dermatology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
ORCID-Profile: Álvaro Martínez-Domenech, Ricardo Fernández-de-Misa Cabrera
Zitieren
APA
Puig, S., Serra-Guillén, C., Pérez-Pastor, G., Martínez-Domenech, Á., & Fernández-de-Misa Cabrera, R. (2022). Experience with sonidegib in patients with advanced basal cell carcinoma: case reports. Drugs in Context, 11, 1-8. https://doi.org/10.7573/dic.2022-3-8
Vancouver
Puig S, Serra-Guillén C, Pérez-Pastor G, Martínez-Domenech Á, Fernández-de-Misa Cabrera R. Experience with sonidegib in patients with advanced basal cell carcinoma: case reports. Drugs in Context. 2022;11:1-8. doi:10.7573/dic.2022-3-8
BibTeX
@article{Puig2022,
author = {Puig, Susana and Serra-Guillén, Carlos and Pérez-Pastor, Gemma and Martínez-Domenech, Álvaro and Fernández-de-Misa Cabrera, Ricardo},
title = {Experience with sonidegib in patients with advanced basal cell carcinoma: case reports},
journal = {Drugs in Context},
year = {2022},
volume = {11},
pages = {1--8},
doi = {10.7573/dic.2022-3-8}
}
EUVIMED